Sleep Hygiene, Sarcopenia, and Cognitive Function in Respiratory Disease

Overview

We aim to clarify the relationship between sleep hygiene and the onset of sarcopenia or cognitive dysfunction using sleep time, arousal, and sleep quality as indicators in COPD or IPF patients, and clarify the effects of sleep hygiene on disease progression and life prognosis.

Full Title of Study: “Examination of the Relationship Between Sleep Hygiene, Sarcopenia, and Cognitive Function in Patients With Chronic Obstructive Pulmonary Disease or Idiopathic Pulmonary Fibrosis”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: December 2024

Detailed Description

Chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF) have been reported to be associated with a high rate of sleep-related disorders such as insomnia, sleep-related hypoventilation, and sleep apnea syndrome.Sleep-related disorders cause symptoms such as daytime sleepiness, decreased ADL, and depression, which causes cognitive dysfunction. Both COPD and IPF have been reported to be associated with cognitive dysfunction. Recently, it has been focused on the relationship between sleep-related disorders and sarcopenia. The relationship between sleep hygiene, cognitive dysfunction, and sarcopenia in the patients with COPD or IPF is not well understood.

Clinical Trial Outcome Measures

Primary Measures

  • Relationship between sleep time at study enrollment and onset of sarcopenia during follow-up period
    • Time Frame: Two years

Secondary Measures

  • Relationship between sleep time at study enrollment and the onset of mild cognitive impairment during follow-up period
    • Time Frame: Two years
  • Relationship between sleep efficiency, arousal at the time of study enrollment and the onset of sarcopenia and mild cognitive impairment during the follow-up period
    • Time Frame: Two years
  • Association of sleep time, sleep efficiency, arousal at the time of study enrollment and hospitalization and death due to COPD exacerbations or IPF exacerbations during follow-up period
    • Time Frame: Two years
  • Relationship between sleep time, sleep efficiency, arousal at the time of study enrollment and changes in grip strength, walking speed, skeletal muscle mass and cognitive function during follow-up period
    • Time Frame: Two years
  • Relationship between sleep time, sleep efficiency, arousal at the time of study enrollment and changes in grip strength, walking speed, skeletal muscle mass and cognitive function at the time of study enrollment
    • Time Frame: Two years
  • Factors associated with the onset of sarcopenia and mild cognitive impairment during follow-up period
    • Time Frame: Two years

Participating in This Clinical Trial

Inclusion Criteria

  • Subjects with COPD or IPF. Exclusion Criteria:

  • Subjects who have been hospitalized for exacerbation of respiratory failure within 1 month of study participation – Subjects who have already been diagnosed with sarcopenia or cognitive dysfunction – Subjects receiving long-term oxygen therapy (LTOT) or non-invasive ventilation therapy (NIV) – Subjects with obstructive sleep apnea who are indicated for continuous positive airway pressure (CPAP) – Subjects with severe complications such as cardiovascular disease, liver disease, renal disease, malignancy, and neurological disease.

Gender Eligibility: All

Minimum Age: 20 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • National Hospital Organization Minami Kyoto Hospital
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.